更多栏目
搜索
China Licensing Deals Tracker: Apr 2021
储旻华·2021-06-10
PharmaDJ
CANbridge Secures Two In-Licensing Deals for Rare Disease Therapies.

China Licensing Deals Tracker: Apr 2021


Writer: Minhua Chu

Editor: Justin Fischer


April 2021 saw a slight decrease in-licensing deals for innovative drugs. Out of a total of 11 deals, seven were in-licensing deals with overseas companies.



Four of these deals' values were disclosed, totaling $832 million. Chinese biopharmaceutical company CANbridge accounts for the lion's share with two deals valued at a total of $591 million.



CANbridge reached two deals with US biotech companies


CANbridge was granted an option to an exclusive license for LB-001, a potential gene editing therapy based on LogicBio Therapeutics's GeneRide platform for methylmalonic acidemia (MMA), in Greater China.


The agreement also includes a worldwide license to develop, manufacture and commercialize gene therapy candidates for treatments for Fabry and Pompe diseases. This is based on LogicBio’s adeno-associated virus (AAV) sL65, the first capsid produced from the LogicBio sAAVy™ platform. The options are for the development of AAV sL65-based treatments for two additional indications.


LogicBio is eligible to receive an upfront payment of $10 million, opt-in fees are triggered upon the exercise of these options along with milestone payments for up to $581 million and up to double-digit royalties on net sales.


CANbridge's other in-licensing deal is also related to experimental candidates for rare diseases. The company obtained the exclusive right from Mirum Pharmaceuticals to develop and commercialize maralixibat — an investigational, orally-administered medication that targets the apical sodium dependent bile acid transporter (ASBT) — in Greater China for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA).


The deal includes an $11 million upfront payment, R&D funding, and up to $109  million in milestones as well as significant double-digit tiered royalties based on net sales.


Ocumension paid $20 million to acquire DME intravitreal implant


Ocumension Therapeutics (Ocumension), a Chinese company specializing in ophthalmology therapies, has acquired an exclusive licensing agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant (ILUVIEN) in Greater China and 12 other countries in Asia. ILUVIEN was developed for the treatment of diabetic macular edema and other retina diseases (excluding uveitis).


Under the terms of the agreement, Ocumension has made a $10 million equity investment in Alimera via a private offering. Additionally, Ocumension will make an upfront payment of $10 million and a potential $89 million in sales-based milestone payments.




文章关键字: China Licensing Deals Tracker CANbridge LB-001 methylmalonic acidemia (MMA) LogicBio Pompe diseases Mirum Pharmaceuticals Alagille syndrome (ALGS) familial intrahepatic cholestasis (PFIC)
194
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明